Compare Suncor Energy Inc. (SU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Suncor Energy Inc. vs TG Therapeutics Inc — how do they compare? Suncor Energy Inc. trades at $63.88 (market cap $74.07B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Suncor Energy Inc. is far larger — about 9.7× TG Therapeutics Inc's market cap, and Suncor Energy Inc. pays a 2.7% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SU | TGTX | |
|---|---|---|
Market Cap | $74.07B | $7.64B |
Sector | Energy | Health |
52-Week High | $69.73 | $59.06 |
52-Week Low | $38.17 | $26.94 |
Enterprise Value | $80.75B | $7.84B |
Dividend Yield | 2.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Suncor Energy (SU) trades at $63.82, up 1.74% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.79, a net income margin of 14.7%, and a robust ROE of 19.25%. Recent Q2 2026 earnings beat estimates, and the company has declared consistent dividends. Leadership transition plans are in place, with Peter Zebedee set to become CEO in 2027.
The outlook is positive, supported by strong cash flow, shareholder returns, and favorable analyst sentiment. Key risks include commodity price volatility and operational challenges. With 74% of analysts rating it a buy and no sell ratings, the stock presents a compelling opportunity for value and income investors, though macroeconomic factors remain a watchpoint.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
